L. Sauer

A Phase II Study of Pembrolizumab in EGFR‐Mutant, PD‐L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

J. Horton, J. Goldman, E. Garon, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors

R. DeMatteo, J. Hecht, Z. Wainberg, 2021, Clinical Cancer Research.

Non–small cell lung cancer clinical trials requiring biopsies with biomarker‐specific results for enrollment provide unique challenges

F. Abtin, D. Elashoff, W. Wallace, 2017, Cancer.

Evaluating Casama: Contextualized semantic maps for summarization of lung cancer studies

Denise R. Aberle, Ricky K. Taira, Alex A. T. Bui, 2018, Comput. Biol. Medicine.

A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC.

J. Goldman, E. Garon, C. Wells, 2018 .